Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1987 2
1990 1
1992 2
1993 1
1994 2
1995 2
1996 5
1997 4
1998 6
1999 2
2000 6
2001 4
2002 2
2003 7
2004 9
2005 8
2006 11
2007 10
2008 10
2009 17
2010 18
2011 33
2012 30
2013 27
2014 28
2015 20
2016 24
2017 22
2018 18
2019 27
2020 28
2021 31
2022 24
2023 33
2024 25
2025 20
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

475 results

Results by year

Filters applied: . Clear all
Page 1
A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
Kim CG, Hong MH, Kim D, Lee BH, Kim H, Ock CY, Kelly G, Bang YJ, Kim G, Lee JE, Kim C, Kim SH, Hong HJ, Park YM, Sim NS, Park H, Park JW, Lee CG, Kim KH, Park G, Jung I, Han D, Kim JH, Cha J, Lee I, Kang M, Song H, Oum C, Kim S, Kim S, Lim Y, Kim-Schulze S, Merad M, Yoon SO, Kim HJ, Koh YW, Kim HR. Kim CG, et al. Among authors: hong hj. Clin Cancer Res. 2024 May 15;30(10):2097-2110. doi: 10.1158/1078-0432.CCR-23-3249. Clin Cancer Res. 2024. PMID: 38457288 Clinical Trial.
4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy.
Cha J, Kim CG, Sim NS, Kim G, Son W, Kim D, Jung Y, Hong HJ, Lee HB, Kim J, Kim J, Yoon SO, Go S, Kim J, Seong E, Baek S, Kim KH, Hong MH, Koh YW, Lee I, Kim HR. Cha J, et al. Among authors: hong hj. Cell Rep Med. 2025 Oct 21;6(10):102408. doi: 10.1016/j.xcrm.2025.102408. Epub 2025 Oct 3. Cell Rep Med. 2025. PMID: 41045934 Free PMC article. Clinical Trial.
Palmar Crease-plasty.
Roh TS, Lee DW, Hong HJ, Yoo WM. Roh TS, et al. Among authors: hong hj. J Plast Reconstr Aesthet Surg. 2010 Jan;63(1):e104-6. doi: 10.1016/j.bjps.2009.01.008. Epub 2009 Feb 28. J Plast Reconstr Aesthet Surg. 2010. PMID: 19251503 No abstract available.
Vancomycin resistance VanS/VanR two-component systems.
Hong HJ, Hutchings MI, Buttner MJ; Biotechnology and Biological Sciences Research Council, UK. Hong HJ, et al. Adv Exp Med Biol. 2008;631:200-13. doi: 10.1007/978-0-387-78885-2_14. Adv Exp Med Biol. 2008. PMID: 18792691 Review.
Dynamics and Regulation of mRNA Cap Recognition by Human eIF4F.
Hong HJ, Guevara MG, Li S, Liu Y, Huang AN, Lin E, Neal A, Xu D, Hai R, Zandi R, O'Leary SE. Hong HJ, et al. bioRxiv [Preprint]. 2025 Jun 27:2025.06.26.660926. doi: 10.1101/2025.06.26.660926. bioRxiv. 2025. PMID: 40667164 Free PMC article. Preprint.
475 results